GUIDED THERAPEUTICS Business Summary

Guided Therapeutics Inc. (GTHP) is a medical technology firm specializing in the development and commercialization of non-invasive diagnostic platforms, primarily generating revenue through the sale of its LuViva® Advanced Cervical Scan devices and associated single-use disposables. The company’s business model is anchored in the biophotonics segment, leveraging proprietary light-scanning technology to identify cervical cancers and precancers at the point of care without surgical biopsies. Revenue streams are further diversified through strategic international distribution and licensing agreements in high-volume markets including China, Turkey, and Indonesia. Within the diagnostic landscape, GTHP competes with players such as Femasys Inc., NeoGenomics Inc., and SeaStar Medical Holding Corp., positioning itself as a niche provider of painless, real-time screening alternatives to traditional colposcopy. Originally co-founded in 1992 by Dr. Mark L. Faupel and Shabbir Bakir Bambot, the company is currently led by Dr. Mark L. Faupel, Ph.D., who serves as President, CEO, COO, and Acting CFO. Dr. Faupel is a veteran in the field of non-invasive diagnostics with over 30 years of experience and 26 U.S. patents to his name. The technical roadmap is overseen by Richard L. Fowler, the Chief Technology and R&D Officer since 2010. The leadership team is supported by a board chaired by Michael C. James, Managing Partner of Kuekenhof Capital Management, and includes prominent directors such as ophthalmic surgeon and principal stockholder Dr. John E. Imhoff and fintech executive Alan Grujic. Notable institutional backing has been provided by investors such as Olive Resource Capital and Kuekenhof Capital Management.